Zobrazeno 1 - 10 of 85 pro vyhledávání: '"Jean A. Hurteau"'
1
Akademický článek
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study
Autor: Dana M. Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A. Hurteau, Jeanne M. Schilder
Publikováno v: Oncology and Therapy, Vol 12, Iss 3, Pp 599-607 (2024)
Abstract Introduction Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes re
Externí odkaz: https://doaj.org/article/877785eaaff34eb1860b79fe8e83b988
Zobrazit plný text záznamu
2
Akademický článek
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study
Autor: Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Publikováno v: Oncology and Therapy, Vol 12, Iss 3, Pp 465-475 (2024)
Abstract Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC). However, data are limited on real-world 1LM nirap
Externí odkaz: https://doaj.org/article/be7e5d732cdc4346b5c2c634f5e5b807
Zobrazit plný text záznamu
3
Akademický článek
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting
Autor: Bobbie J. Rimel, Dana M. Chase, Jessica Perhanidis, Armen A. Ghazarian, Ella Xiaoyan Du, Travis Wang, Jinlin Song, Amanda K. Golembesky, Jean A. Hurteau, Linda Kalilani, Ritu Salani, Bradley J. Monk
Publikováno v: Gynecologic Oncology Reports, Vol 51, Iss , Pp 101332- (2024)
Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) are metabolized either via carboxylesterase (niraparib) or cytochrome P450 (CYP) enzymes (olaparib and rucaparib). Patients with advanced epithelial ovarian cancer (aOC) who recei
Externí odkaz: https://doaj.org/article/24bc1740259343c6a807b2eb7818b81b
Zobrazit plný text záznamu
9
Akademický článek
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
Autor: Obiageli Ezewuiro, Tatyana A Grushko, Masha Kocherginsky, Mohammed Habis, Jean A Hurteau, Kathryn A Mills, Jessica Hunn, Olufunmilayo I Olopade, Gini F Fleming, Iris L Romero
Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0147145 (2016)
There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endo
Externí odkaz: https://doaj.org/article/bd820adbee604921aa45a8094b5ac95a
Zobrazit plný text záznamu
10
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States
Autor: Jinan Liu, Bruno Emond, Eric M. Maiese, Marie-Hélène Lafeuille, Patrick Lefebvre, Isabelle Ghelerter, Caterina Wu, Jean A. Hurteau, Premal H. Thaker
Evaluate systemic therapy utilization patterns and outcomes by line of therapy among patients with advanced/recurrent endometrial cancer (EC) treated in the United States. This retrospective observational study used the Optum Clinformatics Extended D
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707455f2df115f0cc615f228951cc6f0
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje